Home Men Health Study offers probably the most comprehensive look to this point on prostate cancer disparities

Study offers probably the most comprehensive look to this point on prostate cancer disparities

Study offers probably the most comprehensive look to this point on prostate cancer disparities

Cedars-Sinai Cancer investigators have found that Black men respond in addition to white men to systemic therapies for advanced prostate cancer when access to quality healthcare is equal, no matter socioeconomic status. Their study, published today within the peer-reviewed Journal of Clinical Oncology, counters previous research suggesting that Black men receiving these therapies-;which include hormone therapy, chemotherapy and immunotherapy-;fare worse than white men do.

We imagine that is probably the most comprehensive have a look at this issue to this point, and our findings suggest that, under the precise conditions, Black men with metastatic prostate cancer can have outcomes similar to those of white men. We wish all men with advanced prostate cancer to know that, in the precise environment, their outcomes may be promising.”

Jun Gong, MD, medical director of Colorectal Cancer Medicine at Cedars-Sinai Cancer and first writer of the study

Prostate cancer, which affects the small gland that helps make semen, is the No. 1 cancer diagnosis and second-leading explanation for cancer death in Black men. Black men are twice as likely as white men to die of prostate cancer, a proven fact that has been not less than partially attributed to systemic barriers to healthcare for Black men.

Investigators on this study contrasted data from a big database of cancer registries reporting outcomes in every type of healthcare settings with two other forms of data. One set of knowledge was collected in healthcare settings including the Department of Veteran’s Affairs, where access to take care of Black patients and white is more equal. One other set of knowledge was from randomized clinical trials where all prostate cancer patients received the identical treatment, and outcomes for Black versus white patients were compared.

“It was interesting to search out that when Black and white men were provided equal access to the identical therapies, given at the identical dosage and monitored in the identical setting, disparities in outcomes were eliminated,” Gong said.

Gong said that the team’s findings point to the necessity for continued lively recruitment of Black men and other minority groups into prostate cancer clinical trials. Community outreach and education are also needed, together with other efforts to offer more equal-access settings for prostate cancer patients.

“Addressing disparities affecting the health of the varied populations we serve is a priority throughout our institution,” said Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer and the PHASE ONE Foundation Distinguished Chair. “Through our Community Outreach and Engagement efforts and our ongoing research, we’re working to higher understand the aspects contributing to those disparities, including socioeconomic aspects and biological drivers that may be addressed through continued advances in precision medicine.”

Gong and his colleagues have additional studies underway to further explore these issues. One is examining treatment patterns for Black versus white prostate cancer patients throughout the VA, including variety of therapy offered, time from diagnosis to initiation of treatment, and what happens when these aspects are equalized.

A separate study is examining drug compliance in Black versus white metastatic prostate cancer patients, how that affects patient outcomes, and whether Black men fare in addition to white men when patient compliance is equal.


Journal reference:

Gong, J., et al. (2023) Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?. Journal of Clinical Oncology. doi.org/10.1200/JCO.23.0094.


Please enter your comment!
Please enter your name here